A Bioluminescent Reporter Bioassay for In-process Assessment of Chimeric Antigen Receptor Lentiviral Vector Potency

Overview

Journal Antib Ther

Publisher Oxford University Press

Date 2025 Jan 22

PMID 39839908

Authors

Julia K Gilden

Pete Stecha

Jim Hartnett

Mei Cong

Affiliations

Soon will be listed here.

Abstract

Background: Chimeric antigen receptor (CAR)-T-cell therapy is a breakthrough in the field of cancer immunotherapy, wherein T cells are genetically modified to recognize and attack cancer cells. Delivery of the CAR gene is a critical step in this therapy and is usually achieved by transducing patient T cells with a lentiviral vector (LV). Because the LV is an essential component of CAR-T manufacturing, there is a need for simple bioassays that reflect the mechanism of action (MOA) of the LV and can measure LV potency with accuracy and specificity. Common methods for LV quantification may overestimate functional titer and lack a functional readout of LV MOA.

Methods: We developed a bioluminescent reporter bioassay using Jurkat T cells stably expressing a luciferase reporter under the control of an nuclear factor of activated T cells (NFAT) response element and tested its suitability for measuring LV potency.

Results: Jurkat reporter cells can be transduced with CAR LV and combined with target cells, yielding a luminescent signal that is dependent on the identity and potency of the LV used. Bioluminescence was highly correlated with CAR expression. The assay is stability indicating and suitable for use in drug development and quality control settings.

Conclusions: We have developed a simple bioassay for potency testing of CAR LV. The bioassay represents a significant improvement over other approaches to LV quantification because it reflects the MOA of the LV and selectively detects fully functional viral particles, making it ideal for inclusion in a matrix of in-process quality control assays for CAR LV.

References

Murphy L, Marians R, Miller K, Brenton M, Mallo R, Kohler M . Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in chimeric antigen receptor T-cell products. Cytotherapy. 2022; 25(1):94-102. PMC: 10123956. DOI: 10.1016/j.jcyt.2022.09.004. View

Kochenderfer J, Feldman S, Zhao Y, Xu H, Black M, Morgan R . Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009; 32(7):689-702. PMC: 2747302. DOI: 10.1097/CJI.0b013e3181ac6138. View

Geraerts M, Willems S, Baekelandt V, Debyser Z, Gijsbers R . Comparison of lentiviral vector titration methods. BMC Biotechnol. 2006; 6:34. PMC: 1534021. DOI: 10.1186/1472-6750-6-34. View

Honikel M, Olejniczak S . Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules. 2022; 12(9). PMC: 9496564. DOI: 10.3390/biom12091303. View

Abraham R, Weiss A . Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol. 2004; 4(4):301-8. DOI: 10.1038/nri1330. View

Aarnoudse C, Kruse M, Konopitzky R, Brouwenstijn N, Schrier P . TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning. Int J Cancer. 2002; 99(1):7-13. DOI: 10.1002/ijc.10317. View

Tang L, Pan S, Wei X, Xu X, Wei Q . Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Mol Ther. 2023; 31(11):3146-3162. PMC: 10638038. DOI: 10.1016/j.ymthe.2023.09.021. View

Jayaraman J, Mellody M, Hou A, Desai R, Fung A, Pham A . CAR-T design: Elements and their synergistic function. EBioMedicine. 2020; 58:102931. PMC: 7393540. DOI: 10.1016/j.ebiom.2020.102931. View

Freile J, Qi Y, Jacob L, Lobo M, Lourens H, Huls G . A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for screening of immunomodulatory checkpoints and therapeutics. Front Immunol. 2023; 14:1233113. PMC: 10407562. DOI: 10.3389/fimmu.2023.1233113. View

10.

Smole A, Benton A, Poussin M, Eiva M, Mezzanotte C, Camisa B . Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell. 2022; 40(12):1470-1487.e7. PMC: 10367115. DOI: 10.1016/j.ccell.2022.11.006. View

11.

Pavlou M, Babutzka S, Michalakis S . A Bioengineered In Vitro Model to Assess AAV-Based Gene Therapies for Cyclic GMP-Related Disorders. Int J Mol Sci. 2022; 23(9). PMC: 9101586. DOI: 10.3390/ijms23094538. View

12.

Grailer J, Cheng Z, Hartnett J, Slater M, Fan F, Cong M . A Novel Cell-based Luciferase Reporter Platform for the Development and Characterization of T-Cell Redirecting Therapies and Vaccine Development. J Immunother. 2023; 46(3):96-106. PMC: 9988225. DOI: 10.1097/CJI.0000000000000453. View

13.

Darowski D, Jost C, Stubenrauch K, Wessels U, Benz J, Ehler A . P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. Protein Eng Des Sel. 2019; 32(5):207-218. DOI: 10.1093/protein/gzz027. View

14.

Jadlowsky J, Leskowitz R, McKenna S, Karar J, Ma Y, Dai A . Long-term stability of clinical-grade lentiviral vectors for cell therapy. Mol Ther Methods Clin Dev. 2024; 32(1):101186. PMC: 10811425. DOI: 10.1016/j.omtm.2024.101186. View

15.

Salmikangas P, Carlsson B, Klumb C, Reimer T, Thirstrup S . Potency testing of cell and gene therapy products. Front Med (Lausanne). 2023; 10:1190016. PMC: 10196484. DOI: 10.3389/fmed.2023.1190016. View

16.

Birkholz K, Hofmann C, Hoyer S, Schulz B, Harrer T, Kampgen E . A fast and robust method to clone and functionally validate T-cell receptors. J Immunol Methods. 2009; 346(1-2):45-54. DOI: 10.1016/j.jim.2009.05.001. View

17.

Jutz S, Leitner J, Schmetterer K, Doel-Perez I, Majdic O, Grabmeier-Pfistershammer K . Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1. J Immunol Methods. 2016; 430:10-20. DOI: 10.1016/j.jim.2016.01.007. View

18.

Maher J, Brentjens R, Gunset G, Riviere I, Sadelain M . Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2001; 20(1):70-5. DOI: 10.1038/nbt0102-70. View

19.

Crabtree G, Olson E . NFAT signaling: choreographing the social lives of cells. Cell. 2002; 109 Suppl:S67-79. DOI: 10.1016/s0092-8674(02)00699-2. View

20.

Finney H, Akbar A, Lawson A . Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2003; 172(1):104-13. DOI: 10.4049/jimmunol.172.1.104. View